Research programme: Wnt signaling pathway inhibitors - 4SC/Nexigen

Drug Profile

Research programme: Wnt signaling pathway inhibitors - 4SC/Nexigen

Alternative Names: NexC 1004; NexiTides

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator 4SC; Nexigen
  • Class Peptides
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Aug 2016 Preclinical trials in Cancer in Germany (Parenteral)
  • 10 Oct 2013 Early research is ongoing in Germany
  • 16 Apr 2010 Early research in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top